Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase-1, an enzyme that plays a role in the production of blood cells in the bone marrow. Co. is focused on improving the quality of life of patients with cancer and bone marrow diseases in addition to prolonging their lives. Co.'s primary product candidate is bomedemstat for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. The three most common MPNs are myelofibrosis, essential thrombocythemia, and polycythemia vera. The IMGO stock yearly return is shown above.
The yearly return on the IMGO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMGO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|